FDA clears Aidoc artificial intelligence solution for flagging suspected brain aneurysm cases
The U.S. Food and Drug Administration has cleared a new artificial intelligence solution from Aidoc for flagging suspected brain aneurysm cases, the company announced Wednesday.
This marks the ninth FDA clearance for the company, which has offices in Israel and New York, and second in the past 10 days. Aidoc noted that physicians overlook aneurysms on medical images about 10% of the time because of their small size and complexity of blood vessels in the brain.
Its new offering aids by flagging suspected positive cases and communicating those findings to the care team, helping radiologists, neuroendovascular surgeons and neurologists who are managing multiple patients at once.
“In the U.S., there is, tragically, a brain aneurysm rupture every 18 minutes. It’s an acute condition that can quickly turn fatal, so time is of the essence, especially for late night reading,” Elad Walach, co-founder and CEO, said in a statement.
Aidoc also earned 510(k) clearance from the FDA on March 29 for an AI software that triages chest X-rays for pneumothorax.
Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic.